Creation of lysine-deficient mutant lymphotoxin-α with receptor selectivity by using a phage display system-Reference-Cited by-同舟云学术

Creation of lysine-deficient mutant lymphotoxin-α with receptor selectivity by using a phage display system

Published:2010-03 Issue:7 Volume:31 Page:1935-1943
ISSN:0142-9612
Container-title:Biomaterials
language:en
Short-container-title:Biomaterials

Author:

Yoshioka Yasuo,Watanabe Hikaru,Morishige Tomohiro,Yao Xinglei,Ikemizu Shinji,Nagao Chioko,Ahmad Shandar,Mizuguchi Kenji,Tsunoda Shin-ichi,Tsutsumi Yasuo,Mukai Yohei,Okada Naoki,Nakagawa Shinsaku

Publisher

Elsevier BV

Subject

Mechanics of Materials,Biomaterials,Biophysics,Ceramics and Composites,Bioengineering

Reference42 articles.

1. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone;Rosenberg;N Engl J Med,1987

2. A phase II study of recombinant tumor necrosis factor in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group;Skillings;J Immunother,1992

3. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation;Price;Blood,2000

4. Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial;Schmidinger;J Immunother,2001

5. Defective Peyer's patch organogenesis in mice lacking the 55-kD receptor for tumor necrosis factor;Neumann;J Exp Med,1996

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An engineered TNFR1-selective human lymphotoxin-alpha mutant delivered by an oncolytic adenovirus for tumor immunotherapy;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-06

2. Functional Study of TNFR2 Signaling and Drug Discovery Using a Protein Engineering Approach;YAKUGAKU ZASSHI;2022-12-01

3. Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial;Cancer;2017-06-22

4. A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma;Medical Oncology;2016-10-14

5. Development of novel drug delivery systems using phage display technology for clinical application of protein drugs;Proceedings of the Japan Academy, Series B;2016